Cynapsus Therapeutic (CYNAF) 0.5211 $CYNAF
Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
Marketwire - Thu Apr 24, 5:02AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the United States, Europe, Japan and other countries for the acute rescue of "off" motor symptoms of Parkinson's disease.
Cynapsus Therapeutics Inc. : Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
Thomson Reuters ONE - Thu Apr 24, 5:01AM CDT
April 24, 2014
Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277
Marketwire - Fri Mar 28, 5:01AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive interim data from its recently completed healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from "off" episodes. The interim CTH-104 study results indicate that a higher load of drug on the strip does result in a higher amount of drug entering the blood stream.
Cynapsus Therapeutics Inc. : Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277
Thomson Reuters ONE - Fri Mar 28, 5:00AM CDT
PRESS RELEASE
Cynapsus Therapeutics Reports 2013 Financial Results and Highlights Key Developments
Marketwire - Thu Mar 27, 3:01PM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease, today announced its results for the year ended December 31, 2013. Unless specified otherwise, all amounts are in Canadian dollars.
Cynapsus Therapeutics Announces DTC Approval
Marketwire - Thu Feb 27, 8:24AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC" to facilitate electronic settlement of transfers of its common shares in the United States.
Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
Marketwire - Thu Feb 13, 7:02AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson's disease, today announced the appointment of Nan Hutchinson to the Board of Directors.
LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
Marketwire - Fri Feb 07, 8:15AM CST
LifeSci Advisors, LLC announcement for Cynapsus Therapeutics, Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF)
Cynapsus Therapeutics Announces Exercise of Warrants
Marketwire - Thu Jan 23, 3:01PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. Following the exercise of these warrants, Cynapsus has 39,009,335 commons shares, 21,426,439 warrants and 2,691,316 options to purchase common shares outstanding.
Cynapsus Announces Resignation of Chief Scientific Officer
Marketwire - Wed Jan 22, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities.
Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
Marketwire - Mon Jan 13, 5:01AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of "OFF" episodes in Parkinson's disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines.
Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
Marketwire - Thu Apr 24, 5:02AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the United States, Europe, Japan and other countries for the acute rescue of "off" motor symptoms of Parkinson's disease.
Cynapsus Therapeutics Inc. : Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
Thomson Reuters ONE - Thu Apr 24, 5:01AM CDT
April 24, 2014
Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277
Marketwire - Fri Mar 28, 5:01AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive interim data from its recently completed healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from "off" episodes. The interim CTH-104 study results indicate that a higher load of drug on the strip does result in a higher amount of drug entering the blood stream.
Cynapsus Therapeutics Inc. : Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277
Thomson Reuters ONE - Fri Mar 28, 5:00AM CDT
PRESS RELEASE
Cynapsus Therapeutics Reports 2013 Financial Results and Highlights Key Developments
Marketwire - Thu Mar 27, 3:01PM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease, today announced its results for the year ended December 31, 2013. Unless specified otherwise, all amounts are in Canadian dollars.
Cynapsus Therapeutics Announces DTC Approval
Marketwire - Thu Feb 27, 8:24AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company"
(TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC" to facilitate electronic settlement of transfers of its common shares in the United States. Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
Marketwire - Thu Feb 13, 7:02AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson's disease, today announced the appointment of Nan Hutchinson to the Board of Directors.
LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
Marketwire - Fri Feb 07, 8:15AM CST
LifeSci Advisors, LLC announcement for Cynapsus Therapeutics, Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF)
Cynapsus Therapeutics Announces Exercise of Warrants
Marketwire - Thu Jan 23, 3:01PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. Following the exercise of these warrants, Cynapsus has 39,009,335 commons shares, 21,426,439 warrants and 2,691,316 options to purchase common shares outstanding.
Cynapsus Announces Resignation of Chief Scientific Officer
Marketwire - Wed Jan 22, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities.
Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
Marketwire - Mon Jan 13, 5:01AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of "OFF" episodes in Parkinson's disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines.
